#South Korea #Seoul #Lunit #CellCarta #AI Pathology

Lunit and CellCarta: A Strategic Partnership in Advanced Digital Pathology

In a significant step towards transforming cancer diagnostics, Lunit, a prominent AI solutions provider, has announced a strategic collaboration with CellCarta, a leading global contract research organization (CRO). This partnership aims to enhance the implementation of AI-powered digital pathology across the spectrum of translational research, clinical trials, and companion diagnostic (CDx) programs. Together, they seek to provide biopharmaceutical companies an integrated approach to streamline their workflows and accelerate the development of actionable evidence for companion diagnostics.

Meeting a Critical Need in Biopharma

As biopharma organizations increasingly gravitate towards innovative solutions that facilitate faster and more cost-effective clinical pathways, the necessity for an end-to-end strategy has never been clearer. Traditional in vitro diagnostic (IVD) kits can often be cumbersome and slow, delaying critical decisions about the advancement of drug pipelines. Recognizing this challenge, Lunit and CellCarta have designed their collaboration to address these needs.

By merging Lunit's advanced, platform-agnostic AI pathology algorithms with CellCarta's robust infrastructure and expertise in CDx execution, the partnership is poised to create a bridge between CDx development and digital pathology. Specifically, they aim to support single-site CDx development pathways while optimizing laboratory-developed test (LDT) strategies for global trials. This not only accelerates clinical testing but also lays the groundwork for future commercialization.

Key Focus Areas of the Collaboration

The partnership will prioritize a range of critical focus areas:
1. De-risking Support: Assisting sponsors who seek to expedite their timelines and make informed, data-driven decisions to mitigate uncertainty in clinical trials.
2. Translational and Clinical Workflows: Integrating trial execution with Lunit's AI-powered image analysis to bolster biomarker evidence across clinical trials.
3. Platform-Agnostic Implementation: Ensuring the application of AI technology can fit seamlessly within various digital pathology ecosystems, accommodating the operational flexibility that sponsors require.
4. Real-World Global Pilots: The collaboration plans to initiate pilot programs to validate their combined capabilities in real-world settings, focusing on trial operations and AI image analysis.

Vision for the Future

Brandon Suh, CEO of Lunit, expressed, “The rapid transition towards AI-enabled pathology necessitates a foundation of interoperability and operational readiness. Collaborating with CellCarta allows us to meet current workflow demands while paving the way for future commercialization as evidence requirements evolve.” Dusty Tenney, CEO of CellCarta, added, “Our clients require agility without compromising on quality. By merging our global capabilities with Lunit’s advanced AI, we aim to optimize evidence generation and enhance the speed of advancement for the most promising programs.”

Ehab A. El-Gabry, Chief Medical Officer at CellCarta, emphasized the growing importance of digital pathology and validated AI algorithms in developing CDx, underscoring how this collaboration aims to create more consistent and scalable global programs.

Joint Pilot Programs on the Horizon

As part of their strategic commitment, Lunit and CellCarta expect to kick off pilot projects that highlight their combined proficiency. These initiatives will encompass real-world scenarios and further validate their integrated potential in both trial operations and AI image analysis. The goal remains clear: to improve how biopharma teams gather actionable tissue biomarker evidence and better prepare for regulatory demands and commercialization aims.

About Lunit

Founded in 2013, Lunit has established itself as a leader in the fight against cancer through innovative AI technology. The company’s solutions span various medical imaging applications, supporting clinicians in making timely and informed treatment decisions. Their platform has been trusted by over 10,000 medical facilities across more than 65 countries, reflecting their commitment to advancing precision oncology.

About CellCarta

CellCarta is renowned for its extensive expertise in providing biomarker testing services to the biopharmaceutical industry. With locations across multiple countries and certifications that ensure the highest testing standards, the organization integrates analytical capabilities in areas like immunology, histopathology, and proteomics, thereby supporting the full spectrum of drug development.

In summary, the alliance between Lunit and CellCarta marks a significant stride forward in the integration of AI within biopharma, setting the stage for enhanced efficiency, accuracy, and faster advancements in patient care. This collaboration could ultimately redefine the landscape of cancer care and diagnostics as we know it today.